MedTrace Logo

A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

NCT02193217 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2015-02-20

No results posted yet for this study

Summary

The purpose of this study is to explore the cardiac pharmacodynamics, safety and tolerability of MT-1303 in healthy subjects.

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

MT-1303-Low

DRUG

MT-1303-High

DRUG

Fingolimod

DRUG

Placebo

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Peter Sowood, M.D · Mitsubishi Tanabe Pharma Europe Ltd.

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Primary Completion
2014-12-31
Completion
2015-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02193217 on ClinicalTrials.gov